15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells

Archives of Biochemistry and Biophysics

Volumn 487, Issue 2, 2009, Pages 139-145

  Chi, Xiuling ^a   Freeman, Brittany Morgan ^a   Tong, Min ^a   Zhao, Yuhua ^a   Tai, Hsin Hsiung ^a  

^a University of Kentucky   (United States)

Author keywords

15 PGDH; Colon cancer; COX 2; Flurbiprofen; NSAIDs

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DICLOFENAC; FLURBIPROFEN; GELATINASE B; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC SULFONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CANCER CELL; CELL STRAIN HT29; CELL TYPE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN METABOLISM; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLURBIPROFEN; HT29 CELLS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MATRIX METALLOPROTEINASE 9; RNA, MESSENGER; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION;

EID: 67649819322     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2009.05.017     Document Type: Article

References (41)

1. Cha Y.I., and DuBois R.N. Ann. Rev. Med. 58 (2007) 229-252
2. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., and DuBois R.N. Cancer Res. 58 (1998) 362-366
3. Ben-Av P., Crofford L.J., Wilder R.L., and Hla T. FEBS Lett. 372 (1995) 83-87
4. Smith W.L., DeWitt D.L., and Garavito R.M. Ann. Rev. Biochem. 69 (2000) 145-182
5. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., and DuBois R.N. J. Clin. Oncol. 23 (2005) 254-266
6. Tai H.H., Ensor C.M., Tong M., Zhou H., and Yan F. Prostaglandins Other Lipid Mediat. 68-69 (2002) 483-493
7. Ding Y., Tong M., Liu S., Moscow J.A., and Tai H.H. Carcinogenesis 26 (2005) 65-72
8. Backlund M.G., Mann J.R., Holla V.R., Buchanan F.G., Tai H.H., Musiek E.S., Milne G.L., Katkuri S., and DuBois R.N. J. Biol. Chem. 280 (2005) 3217-3223
9. Yan M., Rerko R.M., Platzer P., Dawson D., Willis J., Tong M., Lawrence E., Lutterbaugh J., Lu S., Willson J.K., Luo G., Hensold J., Tai H.H., Wilson K., and Markowitz S.D. Proc. Natl. Acad. Sci. USA 101 (2004) 17468-17473
10. Wolf I., O'Kelly J., Rubinek T., Tong M., Nguyen A., Lin B.T., Tai H.H., Karlan B.Y., and Koeffler H.P. Cancer Res. 66 (2006) 7818-7823
11. Simmons D.L., Botting R.M., Robertson P.M., Madsen M.L., and Vane J.R. Proc. Natl. Acad. Sci. USA 96 (1999) 3275-3280
12. Piazza G.A., Alberts D.S., Hixson L.J., Paranka N.S., Li H., Finn T., Bogert C., Guillen J.M., Brendel K., Gross P.H., Sperl G., Ritchie J., Burt R.W., Ellsworth L., Ahnen D.J., and Pamukcu R. Cancer Res. 57 (1997) 2909-2915
13. Barnes C.J., Cameron I.L., Hardman W.E., and Lee M. Br. J. Cancer 77 (1998) 573-580
14. Davies G., Martin L.A., Sacks N., and Dowsett M. Ann. Oncol. 13 (2002) 669-678
15. Gately S., and Kerbel R. Prog. Exp. Tumor Res. 37 (2003) 179-192
16. Yoneda H., Miura K., Matsushima H., Sugi K., Murakami T., Ouchi K., Yamashita K., Itoh H., Nakazawa T., Suzuki M., and Shirai M. J. Med. Microbiol. 52 (2003) 409-415
17. Tegeder I., Pfeilschifter J., and Geisslinger G. FASEB J. 15 (2001) 2057-2072
18. Liou J.Y., Ghelani D., Yeh S., and Wu K.K. Cancer Res. 67 (2007) 3185-3191
19. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Science 290 (2000) 989-992
20. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., and Eling T.E. Mol. Pharmacol. 59 (2001) 901-908
21. Shureiqi I., Chen D., Lotan R., Yang P., Newman R.A., Fischer S.M., and Lippman S.M. Cancer Res. 60 (2000) 6846-6850
22. Quann E.J., Khwaja F., Zavitz K.H., and Djakiew D. Cancer Res. 67 (2007) 3254-3262
23. Frenkian M., Pidoux E., Baudoin C., Segond N., and Jullienne A. Prostaglandins Leukot. Essent. Fatty Acids 64 (2001) 87-93
24. Frenkian M., Segond N., Pidoux E., Cohen R., and Jullienne A. Prostaglandins 65 (2001) 11-20
25. Tai H.H. Biochemistry 15 (1976) 4586-4592
26. Johnson G.L., and Lapadat R. Science 298 (2002) 1911-1912
27. Yang L., Amann J.M., Kikuchi T., Porta R., Guix M., Gonzalez A., Park K.H., Billheimer D., Arteaga C.L., Tai H.H., DuBois R., Carbone D.P., and Johnson D.H. Cancer Res. 67 (2007) 5587-5593
28. Xun C.Q., Tian Z.G., and Tai H.H. Biochem. J. 279 (1991) 553-558
29. Shin Y., Yoon S.H., Choe E.Y., Cho S.H., Woo C.H., Rho J.Y., and Kim J.H. Exp. Mol. Med. 39 (2007) 97-105
30. Liang K.C., Lee C.W., Lin W.N., Lin C.C., Wu C.B., Luo S.F., and Yang C.M. J. Cell. Physiol. 211 (2007) 759-770
31. Brew K., Dinakarpandian D., and Nagase H. Biochim. Biophys. Acta 1477 (2000) 267-283
32. Kawamori T., Rao C.V., Seibert K., and Reddy B.S. Cancer Res. 58 (1998) 409-412
33. Andrews P., Zhao X., Allen J., Li F., and Chang M. Cancer Chemother. Pharmacol. 61 (2008) 203-214
34. Carabaza A., Cabré F., Rotllan E., Gómez M., Gutiérrez M., García M.L., and Mauleón D. J. Clin. Pharmacol. 36 (1996) 505-512
35. McCracken J.D., Wechter W.J., Liu Y., Chase R.L., Kantoci D., Murray Jr. E.D., Quiggle D.D., and Mineyama Y. J. Clin. Pharmacol. 36 (1996) 540-545
36. King Jr. J.G., and Khalili K. Oncogene 20 (2001) 6864-6870
37. Wechter W.J., Kantoci D., Murray Jr. E.D., Quiggle D.D., Leipold D.D., Gibson K.M., and McCracken J.D. Cancer Res. 57 (1997) 4316-4324
38. Wechter W.J., Leipold D.D., Murray Jr. E.D., Quiggle D., McCracken J.D., Barrios R.S., and Greenberg N.M. Cancer Res. 60 (2000) 2203-2208
39. Grösch S., Schilling K., Janssen A., Maier T.J., Niederberger E., and Geisslinger G. Biochem. Pharmacol. 69 (2005) 831-839
40. Tong M., Ding Y., and Tai H.H. Carcinogenesis 27 (2007) 2170-2179
41. Tegeder I., Niederberger E., Israr E., Guhring H., Brune K., Euchenhofer C., Grosch S., and Geisslinger G. FASEB J. 15 (2001) 592-594